Keyword: Flagship Pioneering
The Flagship Ventures-backed microbiome startup has the strong support of its existing investors, who will contribute $40 million to the IPO.
The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.
Foghorn seeks to unravel chromatin regulation and develop drugs to correct problems with it.
The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the Flagship Pioneering startup races to get into the clinic.
Bob Hugin retires from Celgene, Voyager founder steps down as CEO, Boehringer named new U.S. chief to replace retiring Fonteyne.
Venture capital firm Flagship Pioneering has got a major $618 million in capital, the biggest in its 17-year history, topping its total to $2.3 billion.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.
The series C, which moves Codiak’s total haul up toward $170 million, tees the biotech up to move its lead candidate into clinical trials.
Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer.
The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.